Developing and validating Parkinson's disease subtypes and their motor and cognitive progression

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 89, Issue 12, 2018, Pages 1279-1287

  Lawton, Michael ^a   Ben Shlomo, Yoav ^a   May, Margaret T ^a   Baig, Fahd ^b   Barber, Thomas R ^b   Klein, Johannes C ^b   Swallow, Diane M A ^c   Malek, Naveed ^d   Grosset, Katherine A ^d   Bajaj, Nin ^e   Barker, Roger A ^f   Williams, Nigel ^g   Burn, David J ^h   Foltynie, Thomas ⁱ   Morris, Huw R ⁱ   Wood, Nicholas W ⁱ   Grosset, Donald G ^d   Hu, Michele T M ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d INSTITUTE OF NEUROLOGICAL SCIENCES   (United Kingdom)

^e QUEEN S MEDICAL CENTRE   (United Kingdom)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g CARDIFF UNIVERSITY   (United Kingdom)

^h NEWCASTLE UNIVERSITY   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; PLACEBO;

AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLUSTER ANALYSIS; COGNITION; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG RESPONSE; FACTOR ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PSYCHOLOGICAL WELL-BEING; SLEEP; CLASSIFICATION; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX;

AGED; DISEASE PROGRESSION; FEMALE; HUMANS; LEVODOPA; MALE; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 85050581535     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2018-318337     Document Type: Article

References (27)

1. Espay AJ, Brundin P, Lang AE. Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol 2017;13:119-26.
2. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84:1258-64.
3. Fereshtehnejad SM, Romenets SR, Anang JB, et al. New clinical subtypes of Parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol 2015;72:863-73.
4. Graham JM, Sagar HJ. A data-driven approach to the study of heterogeneity in idiopathic Parkinson's disease: identification of three distinct subtypes. Mov Disord 1999;14:10-20.
5. van Rooden SM, Colas F, Martínez-Martín P, et al. Clinical subtypes of Parkinson's disease. Mov Disord 2011;26:51-8.
6. van Rooden SM, Heiser WJ, Kok JN, et al. The identification of Parkinson's disease subtypes using cluster analysis: a systematic review. Mov Disord 2010;25:969-78.
7. Vu TC, Nutt JG, Holford NH. Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Br J Clin Pharmacol 2012;74:267-83.
8. Latourelle JC, Beste MT, Hadzi TC, et al. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation. Lancet Neurol 2017;16:908-16.
9. Lawton M, Baig F, Rolinski M. Parkinson's disease subtypes in the Oxford Parkinson Disease Centre (OPDC) discovery cohort. J Parkinsons Dis 2015;5:269-79.
10. Malek N, Swallow DM, Grosset KA. Tracking Parkinson's: study design and baseline patient data. J Parkinsons Dis 2015;5:947-59.
11. Szewczyk-Krolikowski K, Tomlinson P, Nithi K, et al. The influence of age and gender on motor and non-motor features of early Parkinson's disease: initial findings from the Oxford Parkinson Disease Center (OPDC) discovery cohort. Parkinsonism Relat Disord 2014;20:99-105.
12. Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 2010;25:2649-53.
13. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
14. Hedeker D, Gibbons RD. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychol Methods 1997;2:64-78.
15. Erro R, Vitale C, Amboni M, et al. The heterogeneity of early Parkinson's disease: a cluster analysis on newly diagnosed untreated patients. PLoS One 2013;8:e70244.
16. Gasparoli E, Delibori D, Polesello G, et al. Clinical predictors in Parkinson's disease. Neurol Sci 2002;23(Suppl 2):s77-78.
17. Lewis SJ, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-8.
18. Liu P, Feng T, Wang YJ, et al. Clinical heterogeneity in patients with early-stage Parkinson's disease: a cluster analysis. J Zhejiang Univ Sci B 2011;12:694-703.
19. Post B, Speelman JD, de Haan RJ, et al. Clinical heterogeneity in newly diagnosed Parkinson's disease. J Neurol 2008;255:716-22.
20. Reijnders JS, Ehrt U, Lousberg R, et al. The association between motor subtypes and psychopathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:379-82.
21. Schrag A, Quinn NP, Ben-Shlomo Y. Heterogeneity of Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:275-6.
22. Fereshtehnejad SM, Zeighami Y, Dagher A, et al. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain 2017;140:1959-76.
23. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and nonmotor outcomes. Lancet Neurol 2011;10:415-23.
24. Chan PL, Nutt JG, Holford NH. Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease. J Pharmacokinet Pharmacodyn 2004;31:243-68.
25. Chan PL, Nutt JG, Holford NH. Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation. Pharm Res 2007;24:791-802.
26. Holford NH, Chan PL, Nutt JG, et al. Disease progression and pharmacodynamics in Parkinson disease-evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006;33:281-311.
27. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132(Pt 11):2947-57.